Navigation Links
Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment
Date:4/1/2008

ially make available up to a further $3.4 million to cornerstone a future product or corporate acquisition.

Dr. Ken Macleod, Principal at Paul Capital Healthcare, said: "As with all of our transactions, we conducted rigorous due diligence on both the clinical and commercial potential of Plethora's male health portfolio. We believe that the products within this portfolio are very well positioned to address the needs of men with sexual dysfunction, a condition that affects 20-30 percent of men at some point during their lifetime. Given this large market, Plethora's male health products are an attractive investment opportunity for our fund."

Dr. Steven Powell, Plethora CEO, commented: "This agreement provides us with financial resources to help fulfil our ambitions for the growth of Plethora. Additionally, this investment by a Paul Capital Healthcare fund is a strong vote of confidence in the commercial prospects of our male health franchise. In a climate where equity based financing would be highly dilutive to shareholders, this non-dilutive finance facility will strengthen our balance sheet and help conclude on-going licensing discussions with regard to PSD502. We also expect that this transaction will maximise value realisation from our male health portfolio, including our Timm Medical operation. Also, along with the increased commitment from ETV Capital S.A., this transaction will facilitate the execution of Plethora's product and corporate development ambitions."

For further information contact:

Plethora Solutions Tel : 020 3077 5400

Steven Powell

Plethora City/Financial Enquiries Tel: 020 7379 5151

Maitland

Brian Hudspith/Liz Morley

Paul Capital Healthcare

Lazar Partners:

Fern Lazar Tel: 1 212 867 1762

Email: flazar@lazarpartners.com

Stephanie S
'/>"/>

SOURCE Paul Capital Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
2. Pharmasset Receives $10 Million of Working Capital
3. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
4. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
5. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
6. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
7. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
8. AspenBio Pharma to Present at the Roth Capital Partners 20th Annual Growth Stock Conference
9. CryoLife to Present at Roth Capital Partners 20th Annual Orange County (OC) Growth Stock Conference
10. WaferGen to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
11. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... ENVIRON , an international environmental, ... Dr. Harvey Clewell III has rejoined the firm ... with senior professionals in ENVIRON’s Health Sciences practice. ... The Hamner Institutes for Health Sciences (The Hamner) ... is Director, Center for Human Health Assessment. , ...
(Date:10/30/2014)... Investor-Edge has initiated coverage on the following ... (NASDAQ: MDVN ), Pharmacyclics Inc. (NASDAQ: ... and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free research on ... . On Wednesday, October 29, 2014, the ... Jones Industrial Average declined 0.18%, to finish the day ...
(Date:10/30/2014)... SoundConnect , an industry leading ... end users the key to turning this already ... adding voice enablement and hybrid audio conferencing. , ... communication tool that includes presence, instant messaging and ... becomes a comprehensive unified communications solution. Adding the ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success and the ... fleet of high volume High Pressure Processing (HPP) systems. , ... to PackExpo this year, which is where we first announced ... Williams, CEO at Avure. “Sales of the new Avure machine ... the challenges of market demand for higher throughput. We sold ...
Breaking Biology Technology:Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3
... the price of soybean seed skyrocketing, soybean growers are looking for ... seeding rate. The research and education director of the North Central ... and profit potential in 2009. , ... Urbandale, Iowa ...
... (ASX: CYT) has today circulated a letter and ... shareholders. The letter provides an update on the ... 2009 and provides recommendations on how to vote ... 2009.(Photo: http://www.newscom.com/cgi-bin/prnh/20090225/NY75105 )The letter and the sample ...
... SEATTLE, Feb. 24 Implicit,Bioscience Ltd today announced ... Eli Lilly and Company. Implicit has paid an,undisclosed ... will also,receive a royalty on future IC14 sales. ... substantial expertise and passion to the,treatment of patients ...
Cached Biology Technology:NCSRP Research Director: "Earlier Planting can Increase Soybean Yields" 2NCSRP Research Director: "Earlier Planting can Increase Soybean Yields" 3Cytopia Letter to Progen Shareholders 2Cytopia Letter to Progen Shareholders 3Cytopia Letter to Progen Shareholders 4Cytopia Letter to Progen Shareholders 5Implicit Licenses Clinical Stage Antibody Program From Lilly 2Implicit Licenses Clinical Stage Antibody Program From Lilly 3
(Date:10/31/2014)... been studying the behavior of approximately 300 wild ... They observed that ravens slowly build alliances through ... they also observed that these affiliative interactions were ... about 50 % of the cases these interventions ... ravens, intervening can be potentially risky when the ...
(Date:10/30/2014)... Restoring wetlands can help reduce or reverse soil ... research in California,s Sacramento-San Joaquin River Delta by ... study, which is one of the first to ... methane as they cycle through wetlands, appears in ... . , Worldwide, agricultural drainage of organic ...
(Date:10/30/2014)... life, cells immediately begin accepting assignments to become a ... humans, are special. The cells of mammalian embryos get ... the protective placenta or to commit to forming the ... research from Michigan State University has revealed key discoveries. ... PLOS Genetics , provide insights into where ...
Breaking Biology News(10 mins):Dartmouth study finds restoring wetlands can lessen soil sinkage, greenhouse gas emissions 2Identifying the source of stem cells 2
... (NYSE: A) today introduced a high-performance ion trap ... life-science researchers to identify 60 to 80 percent ... such as protein identification and biomarker discovery, potentially ... cancer and speeding drug development efforts. The Agilent ...
... frequency of drug resistance in isolates of the AIDS ... urgent necessity. Host genes required to support the replication ... targets, but relatively few appropriate target genes have been ... conducted by Dr. Suzanne Sandmeyer and colleagues at the ...
... D. Anderson Cancer Center have developed a way to test ... chemotherapy drug Taxol are effectively killing tumor cells. They say ... to accurately assess whether patients are responding to these agents, ... , In two different studies being presented at the ...
Cached Biology News:Product improves peptide identification for proteomics research 2Study reveals candidate targets for anti-retroviral therapeutics 2Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol 2Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol 3
... The Human Genetic Cell Bank Service ... ECACC is based on Epstein-Barr Virus (EBV) ... resulting in the production of lymphoblastoid cell ... banked, providing a renewable and expandable source ...
... Panorama Mouse/Rat Tissue Extract Protein Array Kit ... various tissue extracts. The expression of a ... a protein specific antibody. When the antibody ... by a sensitive chemiluminescent or fluorescent signal ...
Glycerol-based mounting medium for immunofluorescence microscopy. Formulated to retard photobleaching of fluorochromes such as fluorescein and rhodamine. Product can also be used as a diluent for fl...
... medium is specifically formulated for mounting tissue ... been stained with immunohistochemical methods for viewing ... use with chromogens, such as AEC, that ... Faramount dries completely when slides are cover-slipped ...
Biology Products: